

Information on the Total Number of Voting Rights (Denominator) following conversion notices NEGMA

Negma Group has converted 200 convertible bonds in Oxurion resulting in a EUR 500,000 capital increase. This is part of Negma Group's EUR 30M Capital Commitment¹ that will allow Oxurion to focus on progressing its novel and differentiated back of the eye drug candidates that are targeting potential market opportunities of over \$12 billion

Leuven, BE, Boston, MA, US – November 3, 2021 – 07.00 AM CET – In accordance with article 15 of the Belgian Act of 2 May 2007 on the disclosure of major participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions, [Oxurion NV](#) (Euronext Brussels: OXUR) (the “Company” or “Oxurion”), announces the below information, following the issuance of 152,439 new ordinary shares on September 29 (as listed on October, 6), 2021 and the issuance of 156,250 new ordinary shares on October 7 (as listed on October 12), 2021, for a total amount of EUR 500,000 (including an issue premium amounting to EUR 55,487.84), as the result of the conversion of (in aggregate) 200 convertible bonds pursuant to the Capital Commitment entered into with Negma Group.

Following these capital increases' completion, the total number of shares issued by Oxurion amounts to 38,600,639 outstanding ordinary shares carrying voting rights (compared to 38,291,950 outstanding ordinary shares previously). This number will be used for the calculation of the percentages of shareholdings.

Therefore, Oxurion publishes the following updated information:

- | | |
|--|---------------|
| • Share capital (EUR) | 55,770,473.16 |
| • Total number of securities with voting rights (all ordinary shares) | 38,600,639 |
| • Total number of ordinary shares (= denominator) | 38,600,639 |
| • Number of outstanding rights to subscribe to securities carrying voting rights not yet issued: | |
| ▪ 761,750 subscription rights (“SR’s”) issued on November 20, 2017, entitling their holders to subscribe to a total number of 761,750 securities carrying voting rights (all ordinary shares); | |
| ▪ 135,000 SR’s issued on December 23, 2020, entitling their holders to subscribe to a total number of 135,000 securities carrying voting rights (all ordinary shares); | |
| ▪ 1,041,000 SR’s issued on April 14, 2021, entitling their holders to subscribe to a total number of 1,041,000 securities carrying voting rights (all ordinary shares); | |

¹ [Press release Oxurion, 06/04/2021](#)

- 410 convertible bonds issued on September 17, 2021, entitling their holder (Negma Group) to subscribe to a total number of securities carrying voting rights (all ordinary shares) in accordance with the terms and conditions set forth in the Issuance and subscription agreement entered into between the Company and Negma Group on August 26, 2021;
- 550,000 SR's issued on September 22, 2021, entitling their holders to subscribe to a total number of 550,000 securities carrying voting rights (all ordinary shares); and
- 600 convertible bonds issued on October 11, 2021, entitling their holder (Negma Group) to subscribe to a total number of securities carrying voting rights (all ordinary shares) in accordance with the terms and conditions set forth in the Issuance and subscription agreement entered into between the Company and Negma Group on August 26, 2021.

END

For further information please contact:

<p><u>Oxurion NV</u></p> <p>Tom Graney Chief Executive Officer Tel: +32 16 75 13 10 tom.graney@oxurion.com</p> <p>Michaël Dillen Chief Corporate Development Tel: +32 479 783 583 michael.dillen@oxurion.com</p>	<p><u>EU</u> <u>MEDISTRAVA Consulting</u> David Dible/ Sylvie Berrebi/Frazer Hall Tel: +44 20 7638 9571 oxurion@medistrava.com</p> <p><u>US</u> <u>Westwicke, an ICR Company</u> Christopher Brinzey Tel: +1 617 835 9304 chris.brinzey@westwicke.com</p>
--	--

About Oxurion

Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to better preserve vision in patients with retinal vascular disorders including diabetic macular edema (DME), the leading cause of vision loss in diabetic patients worldwide as well as other conditions, including wet age-related macular degeneration (wet AMD) and retinal vein occlusion (RVO).

Oxurion is aiming to build a leading global franchise in the treatment of retinal vascular disorders based on the successful development of its two novel therapeutics:

- THR-687 is a highly selective pan-RGD integrin antagonist that is initially being developed as a potential first line therapy for DME patients. Positive topline results in a Phase 1 clinical study assessing THR-687 as a treatment for DME were announced in 2020. Oxurion is currently conducting a Phase 2 clinical trial ("INTEGRAL") evaluating THR-687 in patients with DME. THR-687 also has the potential to deliver improved treatment outcomes for patients with wet AMD and RVO.
- THR-149 is a potent plasma kallikrein inhibitor being developed as a potential new standard of care for the 40-50% of DME patients showing suboptimal response to anti-VEGF therapy. THR-149 has shown positive topline Phase 1 results for the treatment of DME. The Company is currently conducting a Phase 2 clinical trial ("KALAHARI") evaluating multiple injections of THR-149 in DME patients previously showing a suboptimal response to anti-VEGF therapy. Following positive data from Part A of this Phase 2 study (dose selection), the Company has initiated Part B of the study.

Oxurion is headquartered in Leuven, Belgium, and is listed on the Euronext Brussels exchange under the symbol OXUR. More information is available at www.oxurion.com.

Important information about forward-looking statements

Certain statements in this press release may be considered “forward-looking”. Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company’s Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.